Key Insights

Highlights

Success Rate

82% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

13.3%

2 terminated out of 15 trials

Success Rate

81.8%

-4.7% vs benchmark

Late-Stage Pipeline

13%

2 trials in Phase 3/4

Results Transparency

56%

5 of 9 completed with results

Key Signals

5 with results82% success

Data Visualizations

Phase Distribution

11Total
P 1 (2)
P 2 (7)
P 3 (2)

Trial Status

Completed9
Recruiting2
Terminated2
Active Not Recruiting2

Trial Success Rate

81.8%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT06089616RecruitingPrimary

A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT05039515Phase 2TerminatedPrimary

A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).

NCT05394116Phase 3Active Not RecruitingPrimary

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06508021Phase 2Active Not RecruitingPrimary

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT02279095Phase 2CompletedPrimary

An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)

NCT04307953Phase 2RecruitingPrimary

Saracatinib Trial TO Prevent FOP

NCT03312634Phase 3CompletedPrimary

An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.

NCT03188666Phase 2CompletedPrimary

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

NCT04818398Phase 1CompletedPrimary

Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects

NCT04665323CompletedPrimary

An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.

NCT04829773Phase 1CompletedPrimary

Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects

NCT02190747Phase 2CompletedPrimary

An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects

NCT02521792Phase 2TerminatedPrimary

In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects

NCT02322255CompletedPrimary

A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)

NCT02066324CompletedPrimary

Urine Sample Collection From FOP Patients

Showing all 15 trials

Research Network

Activity Timeline